Bioresponsive cancer-targeted polysaccharide nanosystem to inhibit angiogenesis

Fang Yang  
Xueyang Fang  
Wenting Jiang  
Tianfeng Chen  
Department of Chemistry, Jinan University, Guangzhou, China

Abstract: With many desirable features, such as being more effective and having multiple effects, antiangiogenesis has become one of the promising cancer treatments. The aim of this study was to design and synthesize a new targeted bioresponsive nanosystem with antiangiogenesis properties. The mUPR@Ru(POP) nanosystem was constructed by the polymerization of Ulva lactuca polysaccharide and N-isopropyl acrylamide, decorated with methoxy polyethylene glycol and Arg–Gly–Asp peptide, and encapsulated with anticancer complex [Ru(phen)2p-MOPIP](PF6)2⋅2H2O. The nanosystem was both pH responsive and targeted. Therefore, the cellular uptake of the drug was greatly improved. Moreover, the mUPR@Ru(POP) had strong suppressive effects against vascular endothelial growth factor (VEGF)-induced angiogenesis through apoptosis. The mUPR@Ru(POP) significantly inhibited VEGF-induced human umbilical vein endothelial cell migration, invasion, and tube formation. These findings have presented new insights into the development of antiangiogenesis drugs.

Keywords: polysaccharide nanosystem, antiangiogenesis, cancer-targeted, bioresponsive

Introduction
It was reported that the overall cancer death rate dropped 25% from 1991 to 2014 in the USA. But lots of cancers are hardly cured, and some are still very difficult to treat. Chemotherapy, a common cancer treatment to attack cancer cells, can induce severe side effects that may influence a person’s quality of life. Targeting angiogenesis represents a novel strategy for the development of anticancer therapies. Both chemotherapy and antiangiogenesis are systemic treatments, but antiangiogenesis drugs work on where new blood vessels are forming. Therefore, they do not induce severe side effects that chemotherapy does. Antiangiogenesis was proposed in the early 1970s, but until 2004 the first antiangiogenesis drug, Avastin (bevacizumab), was approved by the US Food and Drug Administration (FDA) to treat colon cancer. Bevacizumab is a monoclonal antibody which targets vascular endothelial growth factor (VEGF). It has been established that VEGF is a key driver of sprouting angiogenesis and is overexpressed in most solid cancers. Several other antiangiogenesis drugs have since been approved by the FDA, such as Erbitux (cetuximab), Vectibix (panitumumab), Herceptin (trastuzumab), Nexavar (sorafenib), and Sutent (sunitinib). Some of them are orally active drugs. Antiangiogenesis drugs have become an important part of treatment for many types of cancer.

Ulva lactuca, also known as sea lettuce, is an edible green alga in the division Chlorophyta. Sea lettuce, a food for humans, is eaten raw in salads and cooked in soups. It is a soluble dietary fiber and has high content of protein and high concentrations of iron as well as a variety of vitamins and minerals. It was reported that...
U. lactuca polysaccharides contained glucose, glucuronic acid, xylose, rhamnose, and sulfate groups. Ulva lactuca (UL) polysaccharide exhibited antiviral, anti-oxidative and anti-hyperlipidemic properties.\textsuperscript{10,11} Polysaccharides, as functionalizing agents, have been widely used in cancer nanotechnology because of their excellent biocompatibility, stability, nontoxicity, etc.\textsuperscript{3} The nanomaterials decorated by polysaccharides exhibited enhanced cell-permeating and cancer-targeting abilities.\textsuperscript{12} Therefore, in this study, the nanosystem was originally synthesized by the polymerization of N-isopropyl acrylamide (NIPAM) and UL polysaccharide.

It was reported that the newer antiangiogenesis drugs also attacked tumor cells themselves.\textsuperscript{13,14} The use of antiangiogenesis drugs in conjunction with irradiation and other chemotherapeutic drugs has led to improved treatment outcomes.\textsuperscript{15,16} It is the goal of scientists to design new drugs that are more effective and have multiple effects. In the years to come, such drugs may blur the line between antiangiogenesis drugs and other cancer treatments. In this study, our goal was to design a targeted antiangiogenic nanosystem, which is also pH responsive.\textsuperscript{17} Drug delivery systems with a pH response have been widely used, because they can swell and shrink in different pH condition so as to achieve targeted drug delivery and efficient drug release in cancer cells.\textsuperscript{18,19} The Arg–Gly–Asp (RGD) peptide, an excellent targeting reagent, can recognize the integrin receptor which is overexpressed in a lot of human tumor cells and is able to bind to both tumor cells and endothelial cells.\textsuperscript{20} Therefore, this pH-responsive nanosystem was also decorated with RGD peptide to achieve targeted drug delivery.

In this study, we designed a novel mUPR@Ru(POP) antiangiogenic nanosystem. The polyelectrolyte core of the nanosystem was constructed by the polymerization of U. lactuca polysaccharide and NIPAM and decorated with RGD peptide and methoxyl polyethylene glycol (mPEG). The anticancer complex Ru(POP) ([Ru(phen)2p-MOPIP] (PF6)2·2H2O), an anticancer complex with significant anticancer activity and strong auto-fluorescence, was encapsulated in this nanosystem.\textsuperscript{21,22} The nanosystem overcame the poor stability and low solubility of Ru(POP). It was also pH responsive and targeted, and the cellular uptake of the drug was greatly improved. This mUPR@Ru(POP) had strong suppressive effects against VEGF-induced angiogenesis through apoptosis. It also significantly inhibited VEGF-induced human umbilical vein endothelial cell (HUVEC) migration, invasion, and tube formation both in vitro and in vivo. These findings have provided meaningful insights into the development of antiangiogenesis drugs.

Materials and methods

RGD was obtained from China Gier Biochemistry Company (Shanghai, China). NIPAM, mPEG, N-hydroxysuccinimide (NHS), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), ammonium persulfate (APS), 2-mercapto benzoic acid (MBA), methyl thiazolyl tetrazolium (MTT), propidium iodide (PI), 4′,6-diamidino-2-phenylindole (DAPI), and dihydroethidium (DHE) were purchased from Sigma-Aldrich Co., St Louis (MO, USA). Tetraethylorthosilicate (TEOS), polyethyleneimine (PEI, 99%), triethanolamine, and hexadecyltrimethylammonium bromide (CTAB, 99%) were obtained from Aladdin Chemistry Company (Shanghai, China). The HUVECs were purchased from Guangzhou Jennio Biotech Co., Ltd. (Guangzhou, China).

Preparation of U. lactuca polysaccharide

U. lactuca powder was purchased from Research Center of Hydrobiology of Jinan University (Guangzhou University, China). To extract the polysaccharide, the sample powder was refluxed with ethanol in a water bath for 2 h. Then, the precipitate was heated at 100°C in water (pH =4) for another 2 h. The filtrate was lyophilized, and the polysaccharide was obtained.

Synthesis of mUPR@Ru(POP)

First, NIPAM (0.5 g) and UL polysaccharide (0.25 g) were dissolved in deionized water, and then stirred overnight. Afterward, 0.025 g of MBA was added, and the mixture was heated at 75°C in a three-necked flask with nitrogen gas. Heating of the mixture was continued after the addition of 0.025 g of APS at 60°C for 4 h. After centrifuging and lyophilizing, UL polysaccharide-NIPAM (UP) was obtained. Second, mPEG was decorated to the surface of UP by dissolving UP (500 mg) in water, adding NHS (100 mg), EDC (100 mg), and mPEG (100 mg), and reacting at room temperature for 24 h. mPEG-UL polysaccharide-NIPAM (mUP) was obtained after dialysis for 24 h. Furthermore, NHS, EDC, and RGD were added and stirred for 24 h. mPEG-UL polysaccharide-NIPAM-RGD (mUP) was obtained after 24 h of dialysis. Finally, Ru(POP) was encapsulated in mUP to form mUPR@Ru(POP) by the reaction of mUPR and Ru(POP) for 24 h.

Characterization

The morphology, particle size, and zeta potential of mUPR@Ru(POP) were characterized by transmission electron microscopy (TEM; H-7650; Hitachi Ltd., Tokyo, Japan) and Nano-ZS instrument (Malvern Instruments, Malvern, UK). The Fourier transform infrared (FTIR; Equinox 55; Bruker, Ettlingen, Germany) spectroscopy was conducted in the range of 4,000–500 cm\textsuperscript{-1}.
Cell culture and MTT assay
The HUVECs were cultured in F12 medium including 10% fetal bovine serum (FBS), 0.01% streptomycin, and 1% penicillin in 5% CO₂ atmosphere at 37°C. To perform MTT assay, 2,000 cells/well of HUVECs were seeded in a 96-well plate for 24 h, and different concentrations of mUPR@Ru(POP) were added and incubated for 72 h. Next, 30 μL of MTT was added to each well for 3 h, and then the medium was replaced with dimethyl sulfoxide (DMSO). The cell viability of HUVECs was measured by the absorbance at 570 nm with a microplate spectrophotometer.

In vitro intracellular fluorescence localization
In brief, 20,000 cells/mL of HUVECs were seeded in 2 cm dishes and cultured for 24 h. Next, the mUPR@Ru(POP) was added at different time points. The DAPI and Lyso-Tracker were added preceding the observation time of 0.5 h and 2 h. Finally, the cells were washed with PBS three times and observed by fluorescence microscopy (IX51; Olympus Corporation, Tokyo, Japan).

In vitro cell migration
HUVECs were seeded and incubated in six-well plates for 24 h. Monolayer cells were wounded by 100 μL pipette tips and washed with PBS three times. Fresh medium and mUPR@Ru(POP) were added and incubated for 24 h. Then, the migrated cells were photographed and quantified by manual counting.

In vitro cell invasion
The Boyden chamber is a useful tool to study the effects of mUPR@Ru(POP) on HUVEC invasion. Briefly, the Boyden chamber was precoated with matrigel for 6 h at 37°C. HUVECs (5×10⁴ cells/mL) with serum-free medium were placed in the upper compartment and were allowed to migrate into the lower compartment, in which mUPR@Ru(POP) was present with F12 medium. Nonmigratory cells were scraped off 24 h later, and migratory cells were fixed in methanol, washed, and stained with Giemsa solution. Experiments were performed in triplicate transwells, and the number of cells that migrated to the lower side of the membrane was determined.

In vitro tube formation assay and chorioallantoic membrane assay
The effects of mUPR@Ru(POP) on tube formation and chorioallantoic membrane were evaluated as reported.¹³ Briefly, Matrigel was first thawed at 4°C overnight. Then, 100 μL Matrigel per well was added into prechilled 48-well plate and incubated for 30 min at 37°C to allow the gel to solidify. HUVECs (5×10⁴ cells/mL) were added into the matrigel layer, as well as mUPR@Ru(POP). After 8 h, the tube formation was visualized under an Olympus microscope (Olympus Corporation, Tokyo, Japan). The chorioallantoic membrane (CAM) assay was used to analyze the effect of mUPR@Ru(POP) on angiogenesis in vivo. First, the fertilized eggs were cleaned with 75% ethanol and incubated at 37°C in an egg incubator for 5 days. Then, the eggs were cracked open, and different concentrations of mUPR@Ru(POP), with or without VEGF, were gently injected on the chorioallantoic membrane. After the embryos were incubated for another 2 days, the CAM was observed under an Olympus microscope.

Flow cytometric analysis
As described in our previous paper,¹⁸ the Beckman flow cytometry was used to analyze the cell cycle distribution.

Statistical analysis
Experiments were repeated at least three times. The differences between the treatment groups were analyzed by one-way ANOVA multiple comparisons using SPSS 13.0 statistical package (SPSS Inc., Chicago, IL, USA).

Results and discussion
Characterization of mUPR@Ru(POP)
In this study, a novel cancer-targeting nanosystem, mUPR@Ru(POP), was designed and synthesized (Scheme 1). The polyelectrolyte core was constructed by utilizing the polymerization of NIPAM and UL polysaccharide with APS as an initiator and MBA as a crosslinker, followed by surface modification with mPEG and RGD peptide. According to the previous research,²¹ the decoration of mPEG increased the solubility, stability, and biocompatibility of the nanosystem. Moreover, RGD was a cancer-targeting ligand. Then, this drug delivery system (mUPR) was loaded with anticancer drug Ru(POP) to form mUPR@Ru(POP) (Figure 1A and B). The average particle size of mUPR@Ru(POP) was shown in Figure 1C and D. As shown in Figure 1D, the average particle size of mUPR@Ru(POP) was 250 nm, which was approximately the TEM result as shown in Figure 1C. The TEM showed the image of homogeneous particles with a diameter of about 200 nm, and the nanosystems were stable in 40 days (Figure S1). To determine the stability of mUPR@Ru(POP), the particle sizes in DMEM and DMEM with 10% FBS were observed (Figure 1E). The results showed that the particle sizes had little changes within 24 h in both media. Moreover, the nanoparticles were stable with a diameter of about 300 nm after 30 days. FTIR spectra (Figure 1F) were
used to further characterize the mUPR@Ru(POP) nanosystem. As shown in Figure 1F(a), the peaks at 1,243 cm$^{-1}$ and 1,180 cm$^{-1}$ were contributed to the symmetrical stretching vibration of C–O–C and the stretching vibration of C–N from Ru(POP). These two peaks were also presented in the spectrum of mUPR@Ru(POP) (Figure 1F[d]). The peaks at 1,540 cm$^{-1}$ and 1,380 cm$^{-1}$ were the NH bending for secondary amides and isopropyl group bending vibrations of NIPAM (Figure 1F[b–d]). The peak at 1,600 cm$^{-1}$ corresponded to the stretching vibration of amide from RGD (Figure 1F[c and d]). The difference and appearance of the abovementioned peaks indicated the successful synthesis of mUPR@Ru(POP).

**Scheme 1** Scheme of synthesis of mUPR@Ru(POP).

**Abbreviations:** APS, ammonium persulfate; EDC, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride; MBA, 2-mercapto benzoic acid; mPEG, methoxy polyethylene glycol; mUPR, mPEG-UL polysaccharide-NIPAM-RGD; NHS, N-hydroxysuccinimide; NIPAM, N-isopropyl acrylamide; RGD, Arg-Gly–Asp; RT, room temperature; Ru(POP), [Ru(phen)$_2$P-MOPIP](PF$_6$)$_2$·2H$_2$O; UL, Ulva lactuca; UP, UL polysaccharide-NIPAM.

**pH response of mUPR@Ru(POP)**

Four pH buffer solutions were used to demonstrate the pH-responsive swelling of the mUPR@Ru(POP) nanosystem (Figure 2A–F). The pH 7.4 was similar to the pH of normal tissues and organs; pH 6.8 was the pH of cytoplasm in cancer cells; pH 6.2 was the pH of tumor extracellular environment; pH 5.3 was the pH in lysosome.$^{20}$ The zeta potential and particle size of mUPR@Ru(POP) in different buffer solutions are shown in Figure 2A and D. When the pH decreased from 7.4 to 5.3, the particle size increased from 250 nm to 950 nm, and the surface charge changed from $-25$ mV to $+10$ mV (Figure 2A). TEM (Figure 2B) and a scheme (Figure 1A) were used to further illustrate the pH response of the nanosystem. The TEM images showed that the diameter of the particles was about 200 nm at pH 7.4. However, the diameter of the nanoparticles expanded to about 800 nm when the pH decreased to 5.3 (Figure 2D). Under acidic conditions, there was a change in the ionization state due to the presence of carboxyl and amine group in the nanosystem. This produced an electrostatic repulsion between nanoparticles,$^{24}$ resulting in the swelling of the polyelectrolyte core and the change of particle size. In vitro drug release of Ru(POP) was also performed in different pH values. As shown in Figure 2E, after 48 h, the drug release was about 85% at pH 5.3, which was almost three times more than that at pH 7.4. Therefore, this mUPR@Ru(POP) nanosystem had pH-responsive property which greatly increased the drug release in lysosome.

**Intracellular localization and cellular uptake of mUPR@Ru(POP)**

It was reported that pharmaceutical activity of nanomedicine is mostly dependent on the efficiency of cellular uptake and drug delivery.$^{22}$ The quantitative cellular uptake in HUVECs was originally determined (Figure 2C). HUVECs were treated with 10 μg/mL of Ru(POP), mUP@Ru(POP), and mUPR@Ru(POP). The concentrations of Ru(POP) were detected by inductively coupled plasma mass spectrometry (ICP-MS). The results showed that the intracellular drugs were time dependent. The intracellular concentrations of mUPR@Ru(POP) were the highest, and the intracellular concentrations of Ru(POP) were the lowest. Moreover, Figure 2F...
Figure 1 (A, B) Design, delivery, and action mechanisms of bioresponsive cancer-targeted polysaccharide nanosystem to inhibit angiogenesis. (C) TEM images of mUPr@Ru(POP). (D) Size distribution of mUPr@Ru(POP). (E) Changes in the particle size of mUPr@Ru(POP) following incubation with DMEM or 10% FBS; (F) FTIR spectra of (a) Ru(POP), (b) UP, (c) mUPr, and (d) mUPr@Ru(POP).

Abbreviations: FBS, fetal bovine serum; FTIR, Fourier transform infrared; HUVEC, human umbilical vein endothelial cell; mPEG, methoxy polyethylene glycol; mUPR, mPEG-UL polysaccharide-NIPAM-RGD; NIPAM, N-isopropyl acrylamide; RGD, Arg-Gly-Asp; TEM, transmission electron microscopy; Ru(POP), [Ru(phen)2p-MOPIP](PF6)2⋅2H2O; UL, Ulva lactuca; UP, UL polysaccharide-NIPAM.
Yang et al

Figure 2 (A) Zeta potential of mUPR@Ru(POP) at different pH values. (B) TEM images of mUPR@Ru(POP) at pH 7.4 and 5.3. (C) Quantitative cellular uptake of Ru(POP), mUP@Ru(POP), and mUPR@Ru(POP) in HUVECs (2×10⁵ cells/mL). HUVECs were treated with Ru(POP) (10 μg/mL), mUP@Ru(POP) (10 μg/mL), and mUPR@Ru(POP) (10 μg/mL) for different periods of time. The concentrations of Ru(POP) were determined by ICP-MS. (D) Change in the particle size of mUPR@Ru(POP) with pH value. (E) In vitro drug release of Ru(POP) from mUPR@Ru(POP) in different solution. (F) The cell viability of HUVECs treated with different concentrations of Ru(POP), mUP@Ru(POP), and mUPR@Ru(POP) for 72 h. Each value represents mean ± SD (n=3).

Abbreviations: HUVEC, human umbilical vein endothelial cell; ICP-MS, inductively coupled plasma mass spectrometry; mPEG, methoxy polyethylene glycol; mUP, mPEG-UL polysaccharide-NIPam; mUPR, mPEG-UL polysaccharide-NIPam-RGD; NIPam, N-isopropyl acrylamide; RGD, Arg–Gly–Asp; Ru(POP), [Ru(phen)2P-MOPIP](PF₆)₂·2H₂O; TEM, transmission electron microscopy; UL, Ulva lactuca.

also shows the significant differences of cell viability induced by Ru(POP), mUP@Ru(POP), and mUPR@Ru(POP). The abovementioned results suggested that mUPR@Ru(POP) had a high cellular uptake, and the decoration with RGD as a target molecule greatly enhanced the antiangiogenic activity of mUPR@Ru(POP). Intracellular fluorescence localization was carried out to further investigate whether mUPR@Ru(POP) was in lysosome. As shown in Figure 3, the localization was studied by using Lyso-Tracker (red) to label lysosomes and DAPI to label the nucleus. The overlay results indicated that the drug successfully entered the cells through the lysosomes after treatment for 2 h.
mUPR@Ru(POP) inhibited VEGF-induced cell migration, invasion, and tube formation in vitro

The early stages of angiogenesis have three steps: endothelial cell proliferation, migration, and tube formation.5 To determine whether mUPR@Ru(POP) could suppress the VEGF-induced endothelial cell migration and tube formation, wound healing, Transwell assay, and tube formation assay were performed. As shown in Figures 4A and B and S2, at the concentration of 1 μM, Ru(POP), mUP@Ru(POP) and mUPR@Ru(POP) all strongly inhibited VEGF-induced migration and invasion of HUVECs, but the ability of mUPR@Ru(POP) was the highest. As shown in Figures 4C and S3, tube formation assay was performed to further evaluate the antiangiogenic ability of mUPR@Ru(POP). As expected, VEGF promoted the formation of elongated tube-like structures, but Ru(POP), mUP@Ru(POP), and mUPR@Ru(POP) inhibited the tube formation. Moreover, mUPR@Ru(POP) had the strongest inhibition. Overall, the relative reduced numbers of the migrated cells and invaded cells, as well as the relative decreased length of capillary tube, suggested the significant antiangiogenic ability of mUPR@Ru(POP).

mUPR@Ru(POP) inhibited VEGF-induced CAM angiogenesis

The chick CAM assay is a powerful in vivo angiogenesis model and permits a realistic evaluation of the angiogenic response.22 The abovementioned results showed that mUPR@Ru(POP) inhibited VEGF-induced tube formation in vitro. Therefore, CAM assay was used to further assess the antiangiogenesis of mUPR@Ru(POP) in vivo. As shown in Figures 4D and S4, the formation of branched blood vessels was promoted by VEGF, but mUPR@Ru(POP)
showed a dose-dependent reduction in the branched vessels. Compared to Ru(POP) and mUP@Ru(POP), mUPR@Ru(POP) demonstrated the highest activity. These results suggested that mUPR@Ru(POP) inhibited VEGF-induced CAM angiogenesis.

**Apoptosis induced by mUPR@Ru(POP)**

The mUPR@Ru(POP) nanosystem showed strong suppressive effects against VEGF-induced angiogenesis. So, the effects of synthesized drugs on the cell cycle and apoptosis were analyzed by flow cytometry. After 72 h of incubation with 7.5 μM, 15 μM and 30 μM of mUPR@Ru(POP), the representative DNA histograms (Figure 5) showed a significant increase from 21.9% and 46.7% to 58.8% in the sub-G1 peaks, respectively (Figure S5). When comparing the activity of Ru(POP), mUP@Ru(POP), and mUPR@Ru(POP) at the same concentration of 30 μM, mUPR@Ru(POP) was the highest. These results indicated that

**Figure 4** (A) Ru(POP), mUP@Ru(POP), and mUPR@Ru(POP) (1 μM) inhibited VEGF-induced HUVEC (2×10⁴ cells/mL) migration. (B) mUPR@Ru(POP) (1 μM) inhibited VEGF-induced HUVEC (5×10⁴ cells/mL) invasion. (C) Antiangiogenesis assay mUPR@Ru(POP) (1 μM) on HUVECs (5×10⁴ cells/mL). (D) Representative images of angiogenesis inhibition of ru(POP), mUP@ru(POP), and mUPR@ru(POP) (30 μM) in CAM assay with VEGF.

**Abbreviations:** CAM, chorioallantoic membrane; HUVEC, human umbilical vein endothelial cell; mPeg, methoxy polyethylene glycol; mUP, mPeg-UL polysaccharide-NIPaM; mUPR, mPeg-UL polysaccharide-NIPaM-rgD; NIPaM, N-isopropyl acrylamide; RGD, Arg–Gly–Asp; UL, Ulva lactuca; Ru(POP), [Ru(phen)2p-MOPIP](PF₆)₂⋅2H₂O; VEGF, vascular endothelial growth factor.
Figure 5 Effects of Ru(POP), mUP@Ru(POP), and mUPR@Ru(POP) on HUVEC cycle distribution for 72 h.
Abbreviations: HUVEC, human umbilical vein endothelial cell; mPEG, methoxy polyethylene glycol; mUP, mPEG-UL polysaccharide-NIPaM; mUPR, mPEG-UL polysaccharide-NIPAM-RGD; NIPAM, N-isopropyl acrylamide; RGD, Arg–Gly–Asp; UL, Ulva lactuca; [Ru(phen)2p-MOPIP](PF6)2, 2H2O.

Suppressive effects induced by mUPR@Ru(POP) were mainly through apoptosis.

Conclusion
We successfully synthesized an antiangiogenic mUPR@Ru(POP) nanosystem with the decoration of mPEG and RGD peptide, which improved both the pH response and the cellular uptake of the mUPR@Ru(POP) nanosystem. The targeted mUPR@Ru(POP) could swell in an acidic environment and efficiently release Ru(POP) drug in the lysosome of HUVECs. Moreover, the mUPR@Ru(POP) had strong suppressive effects against VEGF-induced angiogenesis through apoptosis. The mUPR@Ru(POP) significantly inhibited VEGF-induced HUVEC migration and tube formation both in vitro and in vivo. These results have provided new and meaningful insights into the antiangiogenic effects of mUPR@Ru(POP) nanosystem.

Acknowledgment
This work was supported by the Natural Science Foundation of China (21401076, 21271002), National High Technology Research and Development Program of China (863 Program, SS2014AA020538), Science Foundation for Distinguished Young Scholars (S2013050014667) of Guangdong Province, Foundation for High-level Talents in Higher Education of Guangdong, YangFan Innovative & Entrepreneurial Research Team Project (201312H05), Guangdong Special Support Program, and Guangdong Frontier and Key Technological Innovation Special Funds.

Disclosure
The authors report no conflicts of interest in this work.

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA: A Cancer Journal for Clinicians. 2017;67(1):7–30.
2. DeVita VT, Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68(21):8643–8653.
3. Saha B, Haldar U, De P. Polymer-chlorambucil drug conjugates: a dynamic platform of anticancer drug delivery. Macromol Rapid Commun. 2016;37(13):1015–1020.
4. Johnson RP, Jeong YI, John JV, et al. Lipo-poly(L-histidine) hybrid materials with pH-sensitivity, intracellular delivery efficiency, and intrinsic targetability to cancer cells. Macromol Rapid Commun. 2014;35(9):888–894.
5. Sousa EHS, Ridnour LA, Gouveia FS, et al. Thiol-activated HNO release from a ruthenium antiangiogenesis complex and HIF-1α inhibition for cancer therapy. ACS Chem Biol. 2016;11(7):2057–2065.
6. Chen Y, Gao F, Sha X, Fang X. Dual-functional C(RGDYK)-decorated pluronic micelles for antiangiogenesis and drug resistant tumor treatment in vitro. Nanomed Nanotechnol. 2016;12(2):501.
7. Folkman J. Antiangiogenesis in cancer therapy – endostatin and its mechanisms of action. *Exp Cell Res*. 2006;312(5):594–607.
8. Samant RS, Shevde LA. Recent advances in anti-angiogenic therapy of cancer. *Oncotarget*. 2011;2(3):122–134.
9. Ivanova V, Rouseva R, Kolarova M, Serkedjijeva J, Rachev R, Manolova N. Isolation of a polysaccharide with antiviral effect from *Ulva lactuca*. *Prep Biochem*. 1994;24(2):83–97.
10. Nie S, Xing Y, Kim GJ, Simons JW. Nanotechnology applications in cancer. *Ann Rev Biomed Eng*. 2007;9:257–288.
11. Sathivel A, Raghavendran HR, Srinivasan P, Devaki T. Anti-oxidative and anti-hyperlipidemic nature of *Ulva lactuca* crude polysaccharide on D-galactosamine induced hepatitis in rats. *Food Chem Toxicol*. 2008;46(10):3262–3267.
12. Naito H, Wakabayashi T, Kidoya H, et al. Endothelial side population cells contribute to tumor angiogenesis and antiangiogenic drug resistance. *Cancer Res*. 2016;76(11):3200–3210.
13. Jayson GC, Kerbel R, Ellis LM, Harris AL. Antiangiogenic therapy in oncology: current status and future directions. *Lancet*. 2016;388(10043):518–529.
14. Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. *Cancer*. 2004;100(12):2491–2499.
15. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. *Nat Rev Cancer*. 2004;4(6):423–436.
16. Maeda Y, Pitella F, Nomoto T, et al. Fine-tuning of charge-conversion polymer structure for efficient endosomal escape of siRNA-loaded calcium phosphate hybrid micelles. *Macromol Rapid Commun*. 2014;35(13):1211–1215.
17. Hu H, You Y, He L, et al. The rational design of NAMI-A-loaded mesoporous silica nanoparticles as antiangiogenic nanosystems. *J Mater Chem B*. 2015;3(30):6338–6346.
18. Jiang W, Fu Y, Yang F, et al. Gracilaria lemaneiformis polysaccharide as integrin-targeting surface decorator of selenium nanoparticles to achieve enhanced anticancer efficacy. *ACS Appl Mater Interfaces*. 2014;6(16):13738–13748.
19. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. *Nat Nanotechnol*. 2007;2(12):751–760.
20. Fu XY, Yang YH, Li XL, et al. RGD peptide-conjugated selenium nanoparticles: antiangiogenesis by suppressing VEGF-VEGFR2-ERK/AKT pathway. *Nanomedicine*. 2016;12(6):1627–1639.
21. Chen T, Liu Y, Zheng WJ, Liu J, Wong YS. Ruthenium polypyridyl complexes that induce mitochondria-mediated apoptosis in cancer cells. *Inorg Chem*. 2010;49(14):6366–6368.
22. Sun DD, Liu YN, Yu QQ, et al. The effects of luminescent ruthenium(II) polypyridyl functionalized selenium nanoparticles on bFGF-induced angiogenesis and AKT/ERK signaling. *Biomaterials*. 2013;34(1):171–180.
23. Fang XY, Jiang WT, Huang YY, et al. Size changeable nanosystems for precise drug controlled release and efficient overcoming of cancer multidrug resistance. *J Mater Chem B*. 2017;5(5):944–952.
24. Kuhn W, Hargitay B, Katchalsky A, Eisenberg H. Reversible dilation and contraction by changing the state of Ionization of high-polymer acid networks. *Nature*. 1950;165(4196):514–516.
Supplementary materials

Figure S1 The particle size of mUPR@Ru(POP) in 40 days.

Abbreviations: mPEG, methoxy polyethylene glycol; mUPR, mPEG-UL polysaccharide-NIPAM-RGD; NIPAM, N-isopropyl acrylamide; RGD, Arg–Gly–Asp; Ru(POP), [Ru(phen)2p-MOPIP](PF6)2⋅2H2O; UL, Ulva lactuca.

Figure S2 (A) Ru(POP), mUP@Ru(POP), and mUPR@Ru(POP) (1 μM) inhibited VEGF-induced HUVEC (5×10^4 cells/mL) invasion. (B) Antiangiogenesis assay of Ru(POP), mUP@Ru(POP), and mUPR@Ru(POP) (1 μM) on HUVECs (5×10^4 cells/mL).

Note: Magnification is 100×.

Abbreviations: HUVEC, human umbilical vein endothelial cell; mPEG, methoxy polyethylene glycol; mUP, mPEG-UL polysaccharide-NIPAM; mUPR, mPEG-UL polysaccharide-NIPAM-RGD; NIPAM, N-isopropyl acrylamide; RGD, Arg–Gly–Asp; Ru(POP), [Ru(phen)2p-MOPIP](PF6)2⋅2H2O; UL, Ulva lactuca; VEGF, vascular endothelial growth factor.
Figure S3 The relative reduction in the migrated cell numbers, invaded cell numbers, and capillary tube length suggested remarkable anti-metastasis effect of Ru(POP), mUP@Ru(POP), and mUPR@Ru(POP).

Note: The quantitative data were analyzed by manual counting (% of control).

Abbreviations: mPEG, methoxy polyethylene glycol; mUP, mPEG-UL polysaccharide-NIPAM; mUPR, mPEG-UL polysaccharide-NIPAM-RGD; NIPAM, N-isopropyl acrylamide; RGD, Arg–Gly–Asp; Ru(POP), [Ru(phen)2p-MOPIP](PF6)2⋅2H2O; UL, Ulva lactuca; VEGF, vascular endothelial growth factor.
Figure S4 (A) Representative images of angiogenesis inhibition of Ru(POP), mUP@Ru(POP), and mUPR@Ru(POP) (30 μM) in CAM assay without VEGF. (B) The relative quantitation of vascular density based on the CAM images.

Abbreviations: CAM, chorioallantoic membrane; mPEG, methoxy polyethylene glycol; mUP, mPEG-UL polysaccharide-NIPaM; mUPR, mPEG-UL polysaccharide-NIPaM-RGD; NIPaM, N-isopropyl acrylamide; RGD, Arg–Gly–Asp; Ru(POP), [Ru(phen)2p-MOPIP](PF6)2⋅2H2O; Ul, Ulva lactuca; VEGF, vascular endothelial growth factor.

Figure S5 Analysis of sub-G1 value obtained from flow cytometry.
Notes: (A) Effects of Ru(POP), mUP@Ru(POP), and mUPR@Ru(POP) on hUVec cycle distribution for 72 h. (B) Effects of different concentrations of mUPR@Ru(POP) on HUVEC cycle distribution for 72 h.

Abbreviations: HUVEC, human umbilical vein endothelial cell; mPEG, methoxy polyethylene glycol; mUP, mPEG-UL polysaccharide-NIPaM; mUPR, mPEG-UL polysaccharide-NIPaM-RGD; NIPaM, N-isopropyl acrylamide; RGD, Arg–Gly–Asp; Ru(POP), [Ru(phen)2p-MOPIP](PF6)2⋅2H2O; Ul, Ulva lactuca.